Search

Your search keyword '"Edsbäcker S"' showing total 90 results

Search Constraints

Start Over You searched for: Author "Edsbäcker S" Remove constraint Author: "Edsbäcker S"
90 results on '"Edsbäcker S"'

Search Results

1. Colds as predictors of the onset and severity of COPD exacerbations

19. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial

20. Efficacy and Tolerability of an Inhaled Selective Glucocorticoid Receptor Modulator - AZD5423 - in Chronic Obstructive Pulmonary Disease Patients: Phase II Study Results.

21. Seasonal and geographic variations in the incidence of asthma exacerbations in the United States.

23. Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator AZD5423 after Inhalation in Healthy Volunteers.

24. Tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice.

25. Vasoconstriction after inhalation of budesonide: a study in the isolated and perfused rat lung.

26. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.

27. Evidence of the in vivo esterification of budesonide in human airways.

28. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?

29. Airway selectivity: an update of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids.

30. Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation.

31. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.

32. Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules.

33. Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data.

34. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler.

35. The problem of dose-response and therapeutic ratio of inhaled steroids.

36. Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat.

37. Fluticasone and asthma.

38. Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide-esters in vivo.

39. Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol.

40. Comparison of inhaled beclomethasone and budesonide. Study was inadequate.

41. Pharmacological factors that influence the choice of inhaled corticosteroids.

42. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer.

43. [Budesonide is a safe inhalation steroid].

45. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI.

46. Beclomethasone vs budesonide.

47. Oral availability of fluticasone propionate.

48. Relationship between lung tissue and blood plasma concentrations of inhaled budesonide.

49. In vitro biotransformation of glucocorticoids in liver and skin homogenate fraction from man, rat and hairless mouse.

50. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid.

Catalog

Books, media, physical & digital resources